SCHEMBL4171109

SCHEMBL4171109

CCC(C)c1c(F)ccc2c(Cl)nc(Cl)nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919013 0.73 EPRS1 (0.37) —
SCHEMBL29091569 0.72 ALDH1A1 (0.39) —
SCHEMBL4171115 0.71 CCNB2 (0.34) —
SCHEMBL23101917 0.70 HTR2A (0.36) —
SCHEMBL27296836 0.69 MAPT (0.35) —
SCHEMBL27295502 0.69 APP (0.34) —
SCHEMBL23046940 0.67 TSHR (0.34) —
SCHEMBL22166119 0.66 TSHR (0.34) —
SCHEMBL29091614 0.66 ALDH1A1 (0.36) —
SCHEMBL25376794 0.65 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090004185-A1 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2009-01-01 — — US disclosed
WO-2008086462-A2 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2008-07-17 — — WO disclosed
Send feedback